Clinical trials: Allogeneic Stem-Cell Transplant
Myelodysplastic Syndromes, Myelofibrosis
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation
Normal bone marrow function depends on the coexistence of normal hematopoietic stem cells and a microenvironment mostly located in the medullary part of the bones.
- Trial name
- NCT00148980
- Testing
- DBM for creation of bone marrow microenvironment
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Hadassah Medical Organization
Mycosis Fungoides, Sezary Syndrome
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a…
- Trial name
- NCT00047060
- Testing
- A matched peripheral donor stem cells, cyclosporine, fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Primary Progressive Multiple Sclerosis, Multiple Sclerosis
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
- Conditions
- Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06900192
- Testing
- Orca-Q, myeloablative regimen
- Volunteers
- 10 people
- Sponsor
- Stanford University
AML (Acute Myelogenous Leukemia, HSCT
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.
The goal of this clinical trial is to treat adult patients with relapsed/refractory acute myeloid leukemia (AML) using a salvage chemotherapy regimen consisting of Sonrotoclax, cladribine, and standard-dose cytarabine…
- Trial name
- NCT07757672
- Testing
- Sonrotoclax, cladribine, and standard-dose cytarabine
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation
TARC After alloSCT in Hodgkin's Lymphoma
Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure.
- Trial name
- TARC (NCT02069639)
- Testing
- no treatment
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Acute Myeloid Leukemia
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Sorfenib works by slowing the spread of cancer cells. It has been used in other studies for patients with AML with the FLT3-ITD mutation and information from these studies suggests that sorafenib may help to control leukemia.
- Trial name
- NCT01398501
- Testing
- Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Prophylaxis Of Invasive Fungal Infections
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
- Trial name
- VOSIFI (NCT00143312)
- Testing
- voriconazole
- Where
- 17 sites in Belgium, France and 6 more
- Volunteers
- 45 people
- Sponsor
- Pfizer
Adult Lymphoblastic Lymphoma
Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years…
- Trial name
- FluTBI (NCT01991457)
- Testing
- Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Alabama at Birmingham
Acute Myeloid Leukemia, MDS
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
ClAraC (consisting of one dose of clofarabine and ara-C for five days) or FLAMSA (consisting of one dose of fudarabine, amsacrine and ara-C for four days) will be administered followed by reduced-intensity conditioning regimen…
- Trial name
- ClAraC-SCT (NCT01423175)
- Testing
- Clofarabine, ara-C, FLAMSA
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hannover Medical School
Myelodysplastic Syndrome
Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)
To evaluate the feasibility and efficacy of the conditioning regimen with cyclophosphamide, fludarabine and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation (HCT) in patients with lower risk…
- Trial name
- CyFluATG (NCT01255319)
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Cooperative Study Group A for Hematology
Cytomegalovirus Infections
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
- Trial name
- NCT00411645
- Testing
- maribavir
- Where
- 97 sites in United States, Belgium and 7 more
- Volunteers
- 681 people
- Sponsor
- Shire
Multiple Myeloma, Allogeneic Stem Cell Transplantation
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells.
- Trial name
- CARTemis-1 (NCT05982275)
- Testing
- CARTemis-1
- Where
- 5 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
GVHD
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Trial name
- OPTISAGE (NCT06083129)
- Testing
- Grafalon, Thymoglobulin
- Where
- 28 sites in France
- Volunteers
- 324 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Malignant Neoplasm
Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
This clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation.
- Trial name
- NCT02240381
- Testing
- assessment of therapy complications, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Allogeneic Stell Cell Transplant, Viral Infection
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent or treat viral infections that may happen after allogeneic stem cell transplant.
- Trial name
- NCT04230356
- Testing
- Viral Specific T-cells (VSTs) Scheduled, Viral Specific T-cells (VSTs) Treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Invasive Fungal Infections, Hematologic Malignancies
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell…
- Trial name
- NCT00750737
- Testing
- Posaconazole, ABLC
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- Trial name
- NCT02312102
- Testing
- Lenalidomide, Velcade
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Allogeneic Stem Cell Transplantation
HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Human herpesvirus 6 (HHV-6) causes only minor symptoms in healthy individuals but in immunosuppressed patients, e.g., patients after allogeneic stem cell transplantation (HSCT), HHV-6 reactivations can lead to diseases in…
- Trial name
- CIRAST HHV-6 (NCT06256341)
- Testing
- Cell cultivation, Antigen testing
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Leukemia, Lymphoma
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and…
- Conditions
- Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies
- Trial name
- NCT00801931
- Testing
- Alemtuzumab, Total Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.